Hcw Biologics Stock Buy Hold or Sell Recommendation
| HCWB Stock | USD 0.61 0.16 20.78% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding HCW Biologics is 'Strong Sell'. Macroaxis provides HCW Biologics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding HCWB positions.
Check out HCW Biologics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide. In addition, we conduct extensive research on individual companies such as HCW and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards HCW Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.
HCW |
Execute HCW Biologics Buy or Sell Advice
The HCW recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on HCW Biologics. Macroaxis does not own or have any residual interests in HCW Biologics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute HCW Biologics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
HCW Biologics Trading Alerts and Improvement Suggestions
| HCW Biologics is way too risky over 90 days horizon | |
| HCW Biologics has some characteristics of a very speculative penny stock | |
| HCW Biologics appears to be risky and price may revert if volatility continues | |
| HCW Biologics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.84 M. Net Loss for the year was (24.99 M) with profit before overhead, payroll, taxes, and interest of 4.1 M. | |
| HCW Biologics currently holds about 32.41 M in cash with (22.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 52.0% of the company shares are held by company insiders | |
| Latest headline from benzinga.com: Why Keysight Technologies Shares Are Trading Higher By Over 9 Here Are 20 Stocks Moving Premarket |
HCW Biologics Returns Distribution Density
The distribution of HCW Biologics' historical returns is an attempt to chart the uncertainty of HCW Biologics' future price movements. The chart of the probability distribution of HCW Biologics daily returns describes the distribution of returns around its average expected value. We use HCW Biologics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of HCW Biologics returns is essential to provide solid investment advice for HCW Biologics.
| Mean Return | 4.12 | Value At Risk | -13.64 | Potential Upside | 22.00 | Standard Deviation | 41.50 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of HCW Biologics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
HCW Stock Institutional Investors
| Shares | State Street Corp | 2024-06-30 | 21.4 K | Northern Trust Corp | 2024-09-30 | 10.2 K | Tower Research Capital Llc | 2024-06-30 | 6.2 K | Ubs Group Ag | 2024-06-30 | 4.3 K | Royal Bank Of Canada | 2024-06-30 | 407 | Bank Of America Corp | 2024-06-30 | 156 | Wells Fargo & Co | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Jpmorgan Chase & Co | 2024-06-30 | 0.0 | Honkamp Krueger Financial Services Inc | 2024-09-30 | 279.5 K | Geode Capital Management, Llc | 2024-09-30 | 183.3 K |
HCW Biologics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to HCW Biologics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that HCW Biologics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a HCW stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 4.45 | |
β | Beta against Dow Jones | -2.78 | |
σ | Overall volatility | 42.10 | |
Ir | Information ratio | 0.1 |
HCW Biologics Volatility Alert
HCW Biologics is showing large volatility of returns over the selected time horizon. HCW Biologics is a potential penny stock. Although HCW Biologics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in HCW Biologics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on HCW instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.HCW Biologics Fundamentals Vs Peers
Comparing HCW Biologics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze HCW Biologics' direct or indirect competition across all of the common fundamentals between HCW Biologics and the related equities. This way, we can detect undervalued stocks with similar characteristics as HCW Biologics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of HCW Biologics' fundamental indicators could also be used in its relative valuation, which is a method of valuing HCW Biologics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare HCW Biologics to competition |
| Fundamentals | HCW Biologics | Peer Average |
| Return On Equity | -3.44 | -0.31 |
| Return On Asset | -0.7 | -0.14 |
| Operating Margin | (22.36) % | (5.51) % |
| Current Valuation | 44.13 M | 16.62 B |
| Shares Outstanding | 37.82 M | 571.82 M |
| Shares Owned By Insiders | 52.30 % | 10.09 % |
| Shares Owned By Institutions | 3.10 % | 39.21 % |
| Number Of Shares Shorted | 8.09 K | 4.71 M |
| Price To Book | 2.80 X | 9.51 X |
| Price To Sales | 8.24 X | 11.42 X |
| Revenue | 2.84 M | 9.43 B |
| Gross Profit | 4.1 M | 27.38 B |
| EBITDA | (23.58 M) | 3.9 B |
| Net Income | (24.99 M) | 570.98 M |
| Cash And Equivalents | 32.41 M | 2.7 B |
| Cash Per Share | 0.90 X | 5.01 X |
| Total Debt | 6.3 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 30.25 X | 2.16 X |
| Book Value Per Share | (0.17) X | 1.93 K |
| Cash Flow From Operations | (22.51 M) | 971.22 M |
| Short Ratio | 0.28 X | 4.00 X |
| Earnings Per Share | (1.05) X | 3.12 X |
| Target Price | 3.0 | |
| Number Of Employees | 45 | 18.84 K |
| Beta | 0.84 | -0.15 |
| Market Capitalization | 11.95 M | 19.03 B |
| Total Asset | 28.51 M | 29.47 B |
| Retained Earnings | (70.53 M) | 9.33 B |
| Working Capital | (2.34 M) | 1.48 B |
| Net Asset | 28.51 M |
Note: Acquisition by Greene Rick S. of 35714 shares of HCW Biologics at 1.4 subject to Rule 16b-3 [view details]
HCW Biologics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as HCW . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 315423.0 | |||
| Daily Balance Of Power | (0.94) | |||
| Rate Of Daily Change | 0.79 | |||
| Day Median Price | 0.66 | |||
| Day Typical Price | 0.64 | |||
| Price Action Indicator | (0.12) | |||
| Period Momentum Indicator | (0.16) | |||
| Relative Strength Index | 38.04 |
About HCW Biologics Buy or Sell Advice
When is the right time to buy or sell HCW Biologics? Buying financial instruments such as HCW Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having HCW Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Russia On Wall Street Thematic Idea Now
Russia On Wall Street
Cross-sector and cross-instrument bundle of publicly traded Russian entities that are expected to be listed on USA exchanges or over the counter. The Russia On Wall Street theme has 23 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Russia On Wall Street Theme or any other thematic opportunities.
| View All Next | Launch |
Check out HCW Biologics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 0.107 | Quarterly Revenue Growth (0.01) | Return On Assets (0.70) | Return On Equity (3.44) |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.